Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma
These analyses show superior effectiveness of both talquetamab dosing schedules vs sel-dex and vs belamaf for most outcomes and highlight talquetamab as an effective treatment option for patients with TCE RRMM.
Authors
- Ajai Chari (ORCID: https://orcid.org/0000-0003-0053-147X)
- Joris Diels (ORCID: https://orcid.org/0000-0002-9456-9120)
- Suzy Van Sanden
- Donna Reece (ORCID: https://orcid.org/0009-0002-9686-4323)
- Steve Peterson
- Christoph Heuck
- Eric M. Ammann (ORCID: https://orcid.org/0000-0001-5882-5388)
- Lixia Pei
- Colleen Kane
- Anil Londhe
Institutions
- Janssen (Belgium) (BE)
- University of California, San Francisco (US)
- Princess Margaret Cancer Centre (CA)
- Janssen (United States) (US)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1080/03007995.2024.2391553
- Citations
- 1
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.45